Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Acrivon Therapeutics was founded in 2018 by Kristina Masson, Peter Blume-Jensen.
1282 health care and life sciences companies are in the directory, 159 of them in the same 51-100 employee range and 39 based in Greater Boston Area.
Acrivon Therapeutics may be growing as evidenced by a significant rise in their share price and successful private placement financing. The company's shares rose by 59%, which is a strong indicator of investor confidence and market reception. Additionally, Acrivon Therapeutics announced a $130 million private placement financing, which provides substantial capital for the company's operations and growth initiatives. The appointment of a seasoned industry executive to the board suggests strategic strengthening of leadership, which can be instrumental in guiding the company through its growth phase.
“Developing best-in-class targeted therapies to improve the lives of patients.” acrivon.com
Founded in 2018, Acrivon Therapeutics works in biotechnology, health care and oncology from Greater Boston Area and has 51-100 employees. It has raised $245.5 million over 3 rounds and its website drew about 1,622 visits in the latest month measured.
11-50 employees · alxoncology.com
101-250 employees · aveooncology.com
51-100 employees · 1859.ai
51-100 employees · 4basebio.com
101-250 employees · abivax.com
101-250 employees · adimab.com
11-50 employees · a-biodesign.com
251-500 employees · actgenomics.com
11-50 employees · aardvarktherapeutics.com
11-50 employees · advancells.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.